menu
    • menu
    [{"orgOrder":0,"company":"Forbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"PJS-539","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Not Applicable"},{"orgOrder":0,"company":"Forbion","sponsor":"Anaveon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"ANV419","moa":"IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forbion","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"ARMGO Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"F2G Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forbion","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Noema Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Forbion","amount2":0.11,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Kynexis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Forbion","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Calluna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"CAL101","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Forbion","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"SynOx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Forbion","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Progentos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Forbion","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"5","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"LoQus23 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Forbion","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"}]

    Find Clinical Drug Pipeline Developments & Deals by Forbion

    Menu

    Forbion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRB-101

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Recipient : Verdiva Bio

                            Deal Size : $411.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Verdiva Bio Launches With $410M Series A to Develop Next-Gen Therapies

                            Details : The financing aims to advance the clinical development of the company pipeline product, which includes VRB-101 an oral, once-weekly GLP-1 receptor agonist for obesity.

                            Product Name : VRB-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : VRB-101

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Recipient : Verdiva Bio

                            Deal Size : $411.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : LoQus23 Therapeutics

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LoQus23 Secures £35M to Advance Small Molecule Therapy for Huntington's Disease

                            Details : The proceeds from the financing will be primarily used to support the pre-clinical development and initial clinical studies of LoQus23's lead program, an allosteric small molecule MutSβ inhibitor.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : LoQus23 Therapeutics

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Progentos Therapeutics

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Progentos Therapeutics Closes $65 Million Series A Financing for Multiple Sclerosis

                            Details : The financing aims to fund the Progentos, which is developing first-in-class small molecules designed to induce remyelination of axons affected by multiple sclerosis.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Progentos Therapeutics

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : SynOx Therapeutics

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Donesta Safety Study for Menopause Completes Treatment Phase

                            Details : The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : Emactuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : SynOx Therapeutics

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idelalisib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Calluna Pharma

                            Deal Size : $81.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Two biotechs Merge to Form Calluna, with €75M in Hand to Focus on Immunotherapy Antibodies

                            Details : Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for idiopathic pulmonary fibrosis.

                            Product Name : CAL101

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Idelalisib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Calluna Pharma

                            Deal Size : $81.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Kynexis Therapeutics

                            Deal Size : $62.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

                            Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

                            Product Name : KYN-5356

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 07, 2023

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Kynexis Therapeutics

                            Deal Size : $62.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Recipient : Noema Pharma

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Cap...

                            Details : The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and sei...

                            Product Name : NOE-101

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : Basimglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Noema Pharma

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : F2G Limited

                            Deal Size : $70.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Oloro...

                            Details : The proceeds from the financing with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of F901318 (olorofim), a novel oral antifungal therapy to treat invasive aspergillosis and other rare mold infect...

                            Product Name : F901318

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 04, 2022

                            Lead Product(s) : Olorofim

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : F2G Limited

                            Deal Size : $70.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARM210

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : ARMGO Pharma

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ARMGO Pharma Raises $35 Million to Progress Clinical Studies of Lead Molecule ARM210 in Cardiac and Skeletal M...

                            Details : Proceeds will fund further clinical development of its lead asset, ARM210, for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) as well as other cardiac and skeletal muscle indications.

                            Product Name : S48168

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 20, 2021

                            Lead Product(s) : ARM210

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : ARMGO Pharma

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed

                            Forbion

                            Netherlands arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANV419

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Anaveon

                            Deal Size : $119.6 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Anaveon to raise CHF 110 million in oversubscribed Series B financing

                            Details : Proceeds from this financing will enable the Company to pursue multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. ANV419, is designed to signal through the IL-2 beta/gamma receptor and overcome known challen...

                            Product Name : ANV419

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 16, 2021

                            Lead Product(s) : ANV419

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Anaveon

                            Deal Size : $119.6 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth